GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tarsus Pharmaceuticals Inc (NAS:TARS) » Definitions » Pretax Margin %

Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Pretax Margin % : -129.39% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Tarsus Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Tarsus Pharmaceuticals's Pre-Tax Income for the three months ended in Mar. 2024 was $-35.73 Mil. Tarsus Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $27.61 Mil. Therefore, Tarsus Pharmaceuticals's pretax margin for the quarter that ended in Mar. 2024 was -129.39%.

The historical rank and industry rank for Tarsus Pharmaceuticals's Pretax Margin % or its related term are showing as below:

TARS' s Pretax Margin % Range Over the Past 10 Years
Min: -778.89   Med: -240.53   Max: -24.15
Current: -348.22


TARS's Pretax Margin % is ranked worse than
60.14% of 1026 companies
in the Biotechnology industry
Industry Median: -154.275 vs TARS: -348.22

Tarsus Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for Tarsus Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tarsus Pharmaceuticals Pretax Margin % Chart

Tarsus Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial - - -24.15 -240.53 -778.89

Tarsus Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -936.76 - -2,092.36 -320.45 -129.39

Competitive Comparison of Tarsus Pharmaceuticals's Pretax Margin %

For the Biotechnology subindustry, Tarsus Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tarsus Pharmaceuticals's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Tarsus Pharmaceuticals's Pretax Margin % falls into.



Tarsus Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Tarsus Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-135.893/17.447
=-778.89 %

Tarsus Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-35.731/27.614
=-129.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tarsus Pharmaceuticals  (NAS:TARS) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Tarsus Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03 is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Executives
Bobak R. Azamian director, 10 percent owner, officer: President and CEO 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Jose M. Trevejo officer: Chief Medical Officer C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Andrew D. Goldberg director 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Dianne C. Whitfield officer: Chief Human Resources Officer 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Bryan Wahl officer: General Counsel 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Elizabeth Yeu Lin director 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aziz Mottiwala officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Jeffrey S Farrow officer: See Remarks TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Leonard M. Greenstein officer: Chief Financial Officer 24562 BELGREEN PLACE, LAKE FOREST CA 92630
Seshadri Neervannan officer: Chief Operating Officer 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Mark J. Holdbrook officer: V.P., Clinical Affairs 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Michael Ackermann director, 10 percent owner 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Rosemary A Crane director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873